Healthcare Triangle Files 8-K: Agreements, Obligations, and Equity Sales
Ticker: HCTI · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1839285
| Field | Detail |
|---|---|
| Company | Healthcare Triangle, Inc. (HCTI) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.00001, $4.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
Related Tickers: HTRI
TL;DR
HTRI filed an 8-K detailing new agreements, financial obligations, and equity sales.
AI Summary
Healthcare Triangle, Inc. announced on October 21, 2024, that it entered into a material definitive agreement. The company also reported on the creation of a direct financial obligation and triggering events that accelerate or increase such obligations. Additionally, the filing details unregistered sales of equity securities and amendments to its articles of incorporation or bylaws.
Why It Matters
This 8-K filing indicates significant corporate actions by Healthcare Triangle, Inc., including new agreements and financial obligations, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Healthcare Triangle, Inc. (company) — Registrant
- October 21, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Healthcare Triangle, Inc. enter into?
The filing states that Healthcare Triangle, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What are the specific financial obligations mentioned in the 8-K?
The filing indicates the creation of a direct financial obligation and triggering events that accelerate or increase such obligations, but the exact nature and amount of these obligations are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 21, 2024.
Does the filing mention any unregistered sales of equity securities?
Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information.
Are there any amendments to Healthcare Triangle, Inc.'s articles of incorporation or bylaws mentioned?
Yes, the filing includes 'Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year' as an item of information.
Filing Stats: 1,554 words · 6 min read · ~5 pages · Grade level 13 · Accepted 2024-10-25 16:17:21
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share HCTI The Nasdaq Stock Mar
- $4.50 — roval), for a total consideration of at $4.50 per share of Series B Preferred Stock v
Filing Documents
- ea0218708-8k_health.htm (8-K) — 39KB
- ea021870801ex3-1_healthcare.htm (EX-3.1) — 36KB
- ea021870801ex10-1_healthcare.htm (EX-10.1) — 92KB
- 0001213900-24-090797.txt ( ) — 372KB
- hcti-20241021.xsd (EX-101.SCH) — 3KB
- hcti-20241021_lab.xml (EX-101.LAB) — 33KB
- hcti-20241021_pre.xml (EX-101.PRE) — 22KB
- ea0218708-8k_health_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Asset Transfer Agreement On October 21, 2024, the Healthcare Triangle, Inc. (the "Company") acquired substantially all of the business, assets, and operations relating to cloud and technology domain (the "Acquired Assets") of SecureKloud Technologies, Inc., ("Parent"), a Nevada corporation. The Acquired Assets include all of Parent's cloud and technology domain and substantial business interests in the field, that currently form part of the Parent's Business. The Acquired Assets were acquired by the Company under an Asset Transfer Agreement, dated October 21, 2024, between the Company, and the Parent (the "Asset Transfer Agreement"). The consideration for the Acquired Assets consisted of the issuance of 1,600,000 shares of newly designated Series B Convertible Preferred Stock ("Series B Preferred Stock") of the Company, which is/are convertible each into 10 common shares of the Company, at the holder's option (subject to shareholder's approval), for a total consideration of at $4.50 per share of Series B Preferred Stock valuing the transferred assets at USD 7.20 million. The consideration The Asset Transfer Agreement also contained customary representations, warranties, indemnities, and covenants. The closing of the said transaction occurred at the Parent's place of business on October 22, 2024. The description in this report of the Asset Transfer Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement attached hereto as Exhibit 10.1, respectively, which are incorporated by reference herein.
03. Creation of a Direct Financial Obligation
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of the Registrant. The information related to the issuance, sale and exchange of the Series B Convertible Preferred Stock contained in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
04 Triggering Events That Accelerate
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement. As disclosed on the Company's current report on Form 8-K, filed with the SEC on September 10, 2024, the received a notice of default from Seacoast Business Funding, a division of Seacoast National Bank ("Seacoast") with respect to the Purchasing Agreement by and between the Company and Seacoast dated May 2, 2022 ("Purchasing Agreement"). The Company was updated and informed on October 21, 2024 that Seacoast was waiving the foregoing event of Default as of October 18, 2024, and that the Company is now in compliance with the internal terms of the Purchasing Agreement.
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The information related to the issuance, sale and exchange of the Series B Convertible Preferred Stock contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. As described in Item 1.01, pursuant to the terms of the Asset Transfer Agreement, the Company has issued shares of Series B Convertible Preferred Stock to the Parent. This issuance, and sale is and will be exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder. The Parent is an "accredited investors" as defined in Rule 501 of the Securities Act and that the Series B Convertible Preferred Stock is being acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends will be affixed to any certificates evidencing shares of the Series B Convertible Preferred Stock or shares of the Common Stock issued in connection with any future conversion of the Series B Convertible Preferred Stock. 1
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On October 22, 2024, in relation to the Asset Transfer Agreement, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (the " Series B Certificate of Designations ") with the Secretary of State of the State of Delaware to establish the preferences, limitations and relative rights of the Series B Convertible Preferred Stock (the " Series B Convertible Preferred Stock "). The material terms of the Series B Convertible Preferred Stock are summarized below. Description of the Series B Convertible Preferred Stock Conversion Rights Each share of Series B Convertible Preferred Stock has a Stock ") at the option of the holder, after the Stockholder Approval (as may be required by the applicable rules and regulations of The Nasdaq Stock Market LLC (or any successor entity). Voting Rights The holders of the Series B Convertible Preferred Stock are not entitled to vote with the Common Stock. Dividend Rights The holders of the Series B Convertible Preferred Stock are not entitled to receive dividends paid on the Company's Common Stock. Liquidation Rights In the event of liquidation, dissolution, or winding up of the Company, the holders of Series B Convertible Preferred Stock will be entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series B Convertible Preferred Stock if such shares had been converted to Common Stock The foregoing description of the Series B Certificate of Designations does not purport to be complete and is subject to, and is qualified in its entirety by reference to, the full text of the document which is attached hereto as Exhibit 3.1 to this Current Report
Forward Looking Statements
Forward Looking Statements This Current Report contains forward-looking statements that involve risks and uncertainties intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of current or historical fact contained in this Current Report, including statements regarding the Company's expected timeline for compliance with the Nasdaq's Corporate Governance Rules, are forward-looking statements. The words "anticipate," "believe," "continue," "should," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. The Company has based these forward-looking statements on the current expectations about future events held by management. While the Company believes these expectations are reasonable, such forward-looking statements are inherently subject to risks and uncertainties, many of which are beyond the Company's control. The Company's actual future results may differ materially from those discussed here for various reasons. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this Current Report are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. 2
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 3.1 Certificate of Designations of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, dated October 22, 2024. 101. Asset Transfer Agreement, by and between Healthcare Triangle, Inc. and SecureKloud Technologies, Inc., dated October 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Healthcare Triangle, Inc. Date: October 25, 2024 By: /s/ Thyagarajan Ramachandran Name: Thyagarajan Ramachandran Title: Chief Financial Officer 4